A private company founded in 2000 to develop novel biologics to treat cancer, infectious diseases and autoimmune disorders. The company filed an IPO (NASDAQ: MGNX) on October 2013.
Private therapeutics company developing targeted agents for cancer treatment in human clinical trial phase.
Private diagnostic company developing direct detection analysis using the T2MR magnetic biosensor platform.
Private radiopharmaceutical company developing a unique radionuclide for multiple clinical applications including diagnosis and therapy.